GSK3β has been shown to be significantly increased in non-small cell lung cancer patient samples with increased expression correlated with a poor long-term prognosis, and GSK3β was also shown to have inconsistent effects on Wnt/ β-catenin signalling depending on cell-type [7]. Here, GSK3B is linked to non-small cell lung carcinoma.